Journal of Hematology & Oncology

Papers
(The H4-Index of Journal of Hematology & Oncology is 91. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency856
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects846
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans813
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma796
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China753
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018544
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and501
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies408
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening405
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ381
Cytokines and cancer-associated fibroblasts374
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases346
Recent advances in targeting protein degradation for tumor immunotherapy329
Cancer vaccines: current status and future directions316
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024306
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy303
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients288
Landscape of biallelic DNMT3A mutant myeloid neoplasms282
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis276
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression276
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors274
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation257
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2241
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis228
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration221
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway220
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)214
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p210
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts205
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1203
Ferroptosis: principles and significance in health and disease193
Personalized nanovaccines for treating solid cancer metastases193
Recent advances in therapeutic strategies for non-small cell lung cancer193
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma192
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?185
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model184
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation184
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis182
CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies180
Multiple myeloma risk linked to DNA damage response genes178
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia174
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study174
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global 167
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis167
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs165
Small RNA modifications: regulatory molecules and potential applications163
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy162
Recent advances in targeted strategies for triple-negative breast cancer158
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation154
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study151
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry150
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer148
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response148
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting147
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment146
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials145
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects144
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia139
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers137
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype136
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis135
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages134
A single-cell and spatially resolved atlas of human osteosarcomas132
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting129
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts128
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study128
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives127
Target neutrophil heterogeneity and plasticity in cancer127
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia120
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia119
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia119
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting117
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting116
The functional and clinical roles of liquid biopsy in patient-derived models115
Echinomycin as a promising therapeutic agent against KSHV-related malignancies115
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies115
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting114
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial113
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting113
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function108
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis104
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy104
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination103
Challenges and new technologies in adoptive cell therapy97
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies96
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives95
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives94
Gastric cancer treatment: recent progress and future perspectives93
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II 93
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT92
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors91
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial91
1.5703530311584